How Zomacton Dosage Works for Children
Zomacton (somatropin) dosage for children depends on the condition being treated, such as growth hormone deficiency (GHD), idiopathic short stature (ISS), or Turner syndrome. It's always individualized by a doctor based on the child's weight, growth response, and IGF-1 levels, with subcutaneous injections typically given daily. Starting doses are conservative to minimize risks like side effects or excessive growth.[1]
Dosage by Specific Condition
- Growth Hormone Deficiency (GHD): 0.16 to 0.24 mg/kg body weight per week, divided into daily doses (about 0.03 mg/kg/day). Adjust every 1-2 months based on growth velocity and IGF-1.
- Idiopathic Short Stature (ISS): Up to 0.47 mg/kg body weight per week (about 0.067 mg/kg/day), not exceeding 0.067 mg/kg/day.
- Turner Syndrome: 0.375 mg/kg body weight per week (about 0.053 mg/kg/day).
- Small for Gestational Age (SGA): 0.48 mg/kg body weight per week (about 0.067 mg/kg/day) until height reaches genetic potential.
Doses decrease as weight increases; use actual body weight for dosing calculations.[1][2]
Factors Doctors Consider in Adjustments
Weight is the primary metric, but doctors monitor height velocity (aiming for 7-10 cm/year initially), bone age via X-ray, thyroid function, and serum IGF-1 (target: within normal range for age and sex). Treatment starts after confirming diagnosis via stimulation tests. Re-evaluate every 6 months; discontinue if no response after 6-12 months or upon growth plate closure.[1][3]
Administration and Monitoring Schedule
Inject subcutaneously in the evening, rotating sites (thigh, abdomen, upper arm). Use supplied syringes or cartridges; do not shake. Weekly total is split into 6-7 doses. Baseline labs (IGF-1, glucose, thyroid) before starting, then periodically. Annual bone age and funduscopy for intracranial pressure risks.[1][2]
Common Side Effects Tied to Dosage
Higher doses raise risks of fluid retention, joint pain, glucose intolerance, or slipped capital femoral epiphysis. Overdosage can cause acromegaly-like symptoms. Report headaches or vision changes immediately.[1][3]
When to Stop or Switch Treatment
Continue until epiphyses close (typically age 14-16 for girls, 16-18 for boys). For ISS or SGA, reassess at -2.25 SDS height. Biosimilars or alternatives like Norditropin may be considered if switching.[2]
[1]: Zomacton Prescribing Information (FDA-approved label)
[2]: Ferring Pharmaceuticals Zomacton Guidelines
[3]: DrugPatentWatch.com - Zomacton (somatropin) Dosage Overview